About Biocon Biocon's Products & Services Research & Development Biocon's Technology Investors Media Careers CSR
Biocon-Media
     
 

Company Statement

Biocon’s Drug Substance Facility in Bangalore completes U.S. FDA Inspection with No observations

Bengaluru, India, September 22, 2018

“This is to inform you that the U.S. FDA conducted a periodic cGMP inspection of our Drug Substance manufacturing site at Bangalore Campus from Sep 17 - 21, 2018. The weeklong audit concluded without any observations and no Form 483 was issued. The successful audit of this site reflects our strong commitment to cGMP compliance.”  -Company Spokesperson

 

<< Back

 

 
 
 
 
     
  Biocon

Businesses

Recommended sites Biocon on  
  Home
About Us

Investor Relations
Media Relations
Careers
Site Map
Contact Us
Our Growth Accelerators
Fact Sheet
Branded Formulations
Biopharmaceuticals
Research Services
Active Discovery Program

ABLE
Karnataka Vision Group on BT
Syngene International
Biocon Academy

    Linked In   
       
  Report adverse event/side effects and product complaints    
       
  * Disclaimer            © 2018, Biocon. All Rights Reserved